Pfizer Total Alliance revenues — Alliance revenues increased by 10.7% to $2.34B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.7%, from $2.11B to $2.34B. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests successful commercial execution of partnered assets or the expansion of collaborative drug portfolios, while a decrease may indicate maturing partnerships or shifts in strategic alliance focus.
This metric represents the portion of total revenue generated through collaborative arrangements and strategic partnersh...
Similar to 'Collaboration Revenue' or 'Co-promotion Income' reported by large-cap biopharma peers, which often fluctuates based on the lifecycle stage of partnered drugs.
pfe_segment_total_alliance_revenues_alliance_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.91B | $1.91B | $1.91B | $2.31B | $2.32B | $1.69B | $2.22B | $2.06B | $1.97B | $1.65B | $2.11B | $2.34B |
| QoQ Change | — | +0.0% | +0.0% | +21.0% | +0.1% | -27.1% | +31.3% | -7.1% | -4.5% | -16.4% | +28.4% | +10.7% |
| YoY Change | — | — | — | — | +21.1% | -11.7% | +15.9% | -11.0% | -15.1% | -2.6% | — | +10.7% |